Melanocortin Peptide
PT-141 is a synthetic peptide widely studied for its role in melanocortin receptor signaling, central nervous system pathway activation, and sexual response modulation.
Melanocortin Peptide
PT-141
PT-141 is a synthetic peptide widely studied for its role in melanocortin receptor signaling, central nervous system pathway activation, and sexual response modulation.
1
$29.99
Most Popular
Best Value
Est. delivery Jul 20 - Jul 22
Free shipment protection
Secure checkout
We accept:
Free shipping
on orders over $200
Damage protection
on every order
Secure checkout
256-bit SSL
Certificate of Analysis
Tested for Identification, Purity, Mass, Endotoxins, Sterility, and Heavy Metals
LATEST
6× TESTED
99.51%
PURITY
Variant
PT-141 10MG
Lot #
PT141-2606-A01
Labeled
10mg
Actual
10.42mg
Tested
June 21, 2026
Heavy Metals
Within Limits
Endotoxins
Pass
Sterility
No Growth
Compound Information
Pharmaceutical Specifications
Molecular Profile
What Is PT-141?
TypeSynthetic peptide
CAS Number189691-06-3
Molecular FormulaC₅₀H₆₈N₁₄O₁₀
Molecular Weight1,025.17 g/mol
Amino Acids7
Storage Requirements
Stability Information
Lyophilized (powder)
-20°C · 24+ months
Reconstituted
2-8°C · ~30 days
Research
Sources & References
ANNALS OF THE NEW YORK ACADEMY OF SCIENCES (WILEY)
PT-141: A Melanocortin Agonist for the Treatment of Sexual Dysfunction
View Source
INTERNATIONAL JOURNAL OF IMPOTENCE RESEARCH (SPRINGER NATURE)
Evaluation of the Safety, Pharmacokinetics and Pharmacodynamic Effects of Subcutaneously Administered PT-141, a Melanocortin Receptor Agonist, in Healthy Male Subjects and in Patients with an Inadequate Response to Viagra
View Source
UROLOGY (ELSEVIER)
Co-Administration of Low Doses of Intranasal PT-141, a Melanocortin Receptor Agonist, and Sildenafil to Men with Erectile Dysfunction Results in an Enhanced Erectile Response
View Source
JOURNAL OF UROLOGY (WOLTERS KLUWER/AUA)
Salvage of Sildenafil Failures with Bremelanotide: A Randomized, Double-Blind, Placebo-Controlled Study
View Source
OBSTETRICS & GYNECOLOGY (WOLTERS KLUWER/ACOG)
Bremelanotide for the Treatment of Hypoactive Sexual Desire Disorder: Two Randomized Phase 3 Trials
View Source
OBSTETRICS & GYNECOLOGY (WOLTERS KLUWER/ACOG)
Long-Term Safety and Efficacy of Bremelanotide for Hypoactive Sexual Desire Disorder
View Source
JOURNAL OF SEXUAL MEDICINE (ELSEVIER/ISSM)
Responder Analyses from a Phase 2b Dose-Ranging Study of Bremelanotide
View Source
JOURNAL OF WOMEN'S HEALTH (MARY ANN LIEBERT)
Safety Profile of Bremelanotide Across the Clinical Development Program
View Source
JOURNAL OF WOMEN'S HEALTH (MARY ANN LIEBERT)
Prespecified and Integrated Subgroup Analyses from the RECONNECT Phase 3 Studies of Bremelanotide
View Source
